IP Clinic: How is Myriad affecting IP practitioners?
What has been the reaction to the USPTO’s guidelines on the AMP v Myriad Genetics decision from the US Supreme Court?
“Horrifying” USPTO guidelines
I think the guidelines that were promulgated by the USPTO are horrifying to the pharmaceutical and biotech industry. That is probably the nicest thing I could say about them. According to these guidelines not only are natural...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.